Loading the company…
Loading the company…
㈜하이플
English name as filed with DART, Korea’s corporate disclosure system · Correct the English name ›
Last updated 2026-10-11 · Korean page ›
Verification level — how far we have checked
L0 · Public records — NPS workforce · filed financials · patents — public data
A company based in Gyeonggi, founded in 2015. Industry: Wholesale & Retail. Revenue for 2025 was ₩94.9bn. It has 41 employees enrolled in the National Pension Service (as of Aug 2026). It is externally audited; the latest audit opinion is “Unqualified”.
Loading…
Latest filing 2025-02-12 · latest registration 2025-11-14 · newest first
디펩티딜 펩티다제-4(DPP-IV) 억제제이며, 특히 식사 후 혈당 수준을 조절하는 몸의 자연 능력을 향상시키는 방식으로 제 2형 당뇨병 환자의 혈당을 조절하는 당뇨병 치료제로 사용되는 알로글립틴의 제조방법이 개시된다. 상기 알로글립틴의 제조 방법은, 유기 염기의 존재 하에서, 하기 반응식 4에 나타낸 바와 같이, 화학식 (5)로 표시되는 2-((6-클로로-3-메틸-2,4-디옥소-3,4-디히드로피리미딘-1(2H)-일)메틸)벤조니트릴과 화학식 (6)으로 표시되는 (R)-3-아미노피페리딘 디히드로클로라이드를 치환 반응시키는 단계를 포함한다. [반응식 4]
위산 분비 억제 및 위점막 보호 효과를 나타내어 항궤양제로 사용되는 일라프라졸의 새로운 제조방법이 개시된다. 상기 일라프라졸의 제조방법은 하기 화학식 2로 표시되는 2-(((4-메톡시-3-메틸피리딘-2-일)메틸)티오)-5-(1H-피롤-1-일)-1H-벤조[d]이미다졸을 과산화수소수를 이용하여 산화 반응시켜 하기 화학식 1로 표시되는 일라프라졸을 제조하는 단계를 포함한다. [화학식 1] [화학식 2]
KIPO KIPRIS · checked 2026-10-15 · newest filings first · right: registration date (filing date if not yet registered) · 2 of 2 · titles and abstracts are in Korean as filed · click a row for details ▾
For now we hold public records only (National Pension Service · DART filings · patents · registers · press). When the company files material in our IR Room, it moves to L1. We do not score or rate companies — we only state how far we have checked.
| KRW bn | 2024 | 2025 |
|---|---|---|
| Revenue | 95.8 | 94.9 |
| Cost of sales | 84.6 | 84.6 |
| Gross profit (loss) | 11.2 | 10.4 |
| Selling, general and administrative expenses | 6.1 | 7.4 |
| Operating income (loss) | 5.1 | 2.9 |
| Non-operating income | 2.0 | 1.4 |
| Other gains | 0.0 | 0.0 |
| Finance income | 1.0 | 1.0 |
| Other | 1.1 | 0.3 |
| Non-operating expenses | 3.0 | 1.7 |
| Other losses | 0.0 | 0.0 |
| Finance costs | 1.3 | 1.1 |
| Other | 1.7 | 0.6 |
| Profit (loss) before tax | 4.1 | 2.6 |
| Income tax expense | 0.9 | 0.6 |
| Net income (loss) | 3.2 | 2.0 |
Revenue ₩94.9bn, down 0.9% YoY.
Operating margin 3.1% (prior 5.3%).
Net income ₩2bn.
Need more than is shown here? Ask for more information — full review report · valuation · executive teaser · IM · competitor analysis · due diligence. Tell us what you need and we will reply by email with scope, cost and timing.
Is this your company?
If anything here is wrong, tell us — we check it against the original and correct it. You do not need to join. If you would like your financials verified and this page completed, that is a separate process.
Headlines and links to public articles only · not checked by us (original ↗) · articles are in Korean — English headlines are our translation; where none is shown, “Read in English ›” opens a machine translation · “Broker view” is a forecast, not reported results · checked 2026-11-05